Bibliografisk note

Funding Information:
Jan Astermark: has received research grants from Sobi, CSL Behring, Takeda/Shire, and Bayer. Speakers fee and consultant for Octapharma, Novo Nordisk, Pfizer, Bayer, Sobi, CSL Behring, Takeda/Shire, BioMarin, Uniqure, and Spark Therapeutics. Katharina Holstein: received honoraria for Advisory Boards and/or speaker fees from Bayer, Biotest, CSL Behring, Novo Nordisk, Pfizer, Roche, Shire/Takeda, Sobi, and unrestricted grants from Bayer, CSL Behring and Pfizer. Yasmina L. Abajas: has no competing interests to declare. Susan Kearney: has no competing interests to declare. Stacy E. Croteau: has received honoraria or consulting fees from Bayer, Biomarin, CSL‐Behring, Hemabiologics, and Pfizer and she has received institutional research funding from Spark Therapeutics and Novo Nordisk. Riana Liesner: has received consultancy fees, speakers fees, and/or travel support from Octapharma, SOBI, and CSL Behring. Eva Funding: has received honoraria from Roche and Shire, and chaired a symposium for Roche. Eva Funding was invited to ISTH 2015 by Novo Nordisk, EAHAD 2016 by Octapharma, ASH 2016 by Shire, EAHAD 2017 by Pfizer, and to an AOP orphan pharmaceuticals meeting in 2019. Christine L. KemptonSuchitra Acharya: has received honoraria from Spark Therapeutics and Takeda. Received research support from Novo Nordisk. Suchitra Acharya: received research funding for investigator‐initiated study from Bayer. Advisory Board: Novo Nordisk and BPL. Stefan Lethagen: a full‐time employee of Sobi. Petra LeBeau: has received research funding from Takeda, Biogen/Bioverativ and Sobi. Joel Berntorp: has received educational grant from BioMarin. Erik Berntorp: has acted as paid consultant to Bayer, CSL Behring, Octapharma, Sobi, Takeda, and has received funding for research carried out in this work from Sobi and Bioverativ. Amy D. Shapiro: Dr. Shapiro reports the following; however, she does not retain any personal honoraria. All is paid to the Indiana Haemophilia and Thrombosis Centre, Inc. Dr. Shapiro does not have personal financial interest in any healthcare related companies. Clinical research support: Agios, BioMarin, Bioverativ, Daiichi Sankyo, Genentech (Roche), Glover Blood Therapeutics, Kedrion Biopharma, Novartis, Novo Nordisk, OPKO, Octapharma, Pfizer, ProMetic Bio Therapeutics, Sangamo, Takeda. Speaker's Bureau: Genentech (Roche), Novo Nordisk. Advisory Board: Bioverativ, Genentech, Novo Nordisk, Sangamo, Sigilon Therapeutics.

Funding Information:
The authors thank the participants who volunteered to enrol in B‐Natural. The investigators and haemophilia treatment centres in order of contribution: Margaret V. Ragni, MD, MPH and Amy Steele, BSN, RN, University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA; Amy D. Shapiro, MD, and Kathleen F. Molitor, BSN, RN‐BC, CCRC, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA; Munira Borhany, MD, MBBS, MCPS, FCPS and Madiha Abid, PharmD, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan; Yasmina Abajas, MD and Marcus Allen Layer, MPH, Hemophilia and Thrombosis Center, University of North Carolina, Chapel Hill, NC, USA; Jan Astermark, MD, PhD, Malin Axelsson, and Marcus Ljungkvist, BSc, PhD, Department of Translational Medicine, Lund University and Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden; Michael D. Tarantino, MD, and Sarah Gonzales, BS, MT (ASCP), CCRP, Bleeding and Clotting Disorders Institute, Peoria, IL, USA; Katharina Holstein, MD, University Medical Center Hamburg‐Eppendorf, Medical Department, Haemophilia Center, Hamburg, Germany; Stacy E. Croteau, MD and Emily Coe, Boston Children's Hospital, Boston Hemophilia Center, Boston, MA, USA; Raina Liesner, MA, MBBChir, MD, FRCPath, FRCPCH, Anja Griffioen and Alpha Barrie, MSc, Great Ormond Street Hospital for Children, NHS Trust supported by NIHR, GOSH, BRC, London, UK; Cristina Tarango, MD and Amanda Pfeiffer, MA, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Manuela Carvalho, MD, Congenital Coagulopathies Reference Centre, Centro Hospitalar Universitário São João, Porto, Portugal; Catherine McGuinn, MD and Ilene Goldburg, RN, Weill Cornell Medical College, New York, NY, USA; Eva Funding, MD, Department of Hematology, University Hospital Rigshospitalet, Copenhagen, Denmark, Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Christine L. Kempton, MD, MSc and Stephanie Whitten, CCRP, Emory University School of Medicine, Emory University, Atlanta, GA, USA; Christoph Bidlingmaier, MD, Dr. v. Hauner's Childrens University Hospital, Hemophilia Center, LMU Hospital, Munich, Germany; Alice Cohen, MD and Ellen White, RN, MSN, Newark Beth Israel Medical Center, Newark, NJ, USA; Johannes Oldenburg, MD, PhD, Kerstin Liphardt, PhD, and Thilo Albert, PhD, University Clinic Bonn, Bonn, Germany; Susan Kearney, MD and Ashley Kinsella, BS, Children's Minnesota Center for Bleeding and Clotting Disorders, Minneapolis, MN, USA; Christine Knoll, MD, Erica Olson, RN, BA and Courtney Moyer, CCRP, Phoenix Children's Hospital, Phoenix, AZ, USA; Philip Kuriakose, MD and Laura Gusba, NP, Henry Ford Hospital, Detroit, MI, USA; Suchitra Acharya, MD and Joseph Stanco, RN, Northwell Hemostasis and Thrombosis Center, New Hyde Park, New York, NY, USA; Ulrike M. Reiss, MD and Megan Wilson, MSW, CCRP, St. Jude Children's Research Hospital, Memphis, TN, USA; Roshni Kulkarni, MD and Kathleen Anderson, RN, Michigan State University, East Lansing, MI, USA; Michelle Witkop, DNP, FNP‐BC and Stephanie Roessler, Northern Regional Bleeding Disorders Center, Munson Medical Center, Traverse City, MI, USA. B‐Natural is funded through an investigator‐initiated academic collaboration with, Biogen/Bioverativ/Sanofi, Paris, France and Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden.

Publisher Copyright:
© 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd.